Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 7/20 | 0.40 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | EP300 | Q09472 | 2/20 | 0.40 |
| ▸ | TAF1 | P21675 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672582 | 0.94 | CHRM1 (0.49) | CHRM1CREBBPBRD4EP300TAF1 | |
| SCHEMBL23672591 | 0.91 | CHRM1 (0.42) | CHRM1 | |
| SCHEMBL23672965 | 0.90 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL23673023 | 0.90 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL23672732 | 0.89 | CHRM1 (0.47) | CHRM1 | |
| SCHEMBL23672950 | 0.89 | CHRM1 (0.46) | CHRM1CREBBPBRD4 | |
| SCHEMBL23673132 | 0.86 | CHRM1 (0.64) | CHRM1CREBBPBRD4EP300 | |
| SCHEMBL23672832 | 0.86 | CHRM1 (0.45) | CHRM1CREBBP | |
| SCHEMBL23673028 | 0.84 | CHRM1 (0.53) | CHRM1CREBBPBRD4 | |
| SCHEMBL23673076 | 0.84 | AXL (0.40) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | claimed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | claimed |
| EP-3416639-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CREBBP 779/4885BRD4 479/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885CREBBP 779/4885BRD4 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.